Applegate, Tanya Lynn <br/><br/>
In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.  [electronic resource] 

 -  Retrovirology  Oct 2010 
 - 83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1742-4690 
<br/><br/><label>Standard No.: </label>10.1186/1742-4690-7-83  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Retroviral Agents--therapeutic use<br/>Drug Resistance, Viral<br/>Genetic Therapy<br/>HIV Infections--drug therapy<br/>HIV-1--genetics<br/>Hematopoietic Stem Cells--immunology<br/>Humans<br/>Models, Biological<br/>RNA, Small Interfering--genetics<br/>Stochastic Processes<br/>Virus Replication--genetics